DLin-M-C3-DMA

DLin-M-C3-DMA (MC3) is an ionizable cationic lipid that has been used in the generation of lipid nanoparticles (LNPs) encapsulating siRNA, mRNA, or plasmid DNA for use in vitro and in vivo. As a potent siRNA delivery vehicle, DLin-M-C3-DMA facilitates the electrostatic complexation of negatively charged nucleic acids and promotes endosomal escape due to its pH‑dependent charge switching behavior. Clinically, DLin-M-C3-DMA has been employed in LNPs encapsulating transthyretin‑directed siRNA for the treatment of hereditary transthyretin‑mediated amyloidosis‑induced polyneuropathy (Onpattro®). The two polyunsaturated linoleyl tails in DLin-M-C3-DMA contribute to its low toxicity profile and efficient gene silencing activity, with an ED₅₀ of 0.005 mg/kg achieved in murine Factor VII models. For these reasons, DLin-M-C3-DMA remains the benchmark ionizable lipid against which novel LNP formulations are compared.

Product Parameters

Why Cosperpharm? – Our Competitive Advantages

FAQ

Q1: What is DLin-M-C3-DMA?

A: DLin-M-C3-DMA (MC3) is an ionizable cationic lipid that serves as a potent siRNA delivery vehicle in lipid nanoparticles (LNPs). It is the key ionizable lipid in Onpattro® (patisiran), the first FDA‑approved siRNA therapeutic.

Q2: Is DLin-M-C3-DMA soluble in aqueous buffers?

A: DLin-M-C3-DMA is insoluble in water. It is soluble in organic solvents including ethanol, DMSO, DMF, and chloroform. For LNP formulation, lipids are dissolved in ethanol before mixing with aqueous nucleic acid solutions.

Application Scenarios

1. siRNA Therapeutic Development

DLin-M-C3-DMA is the clinically validated ionizable lipid for siRNA delivery, used in Onpattro® (patisiran) for hereditary transthyretin‑mediated amyloidosis. It is the benchmark lipid for hepatic gene silencing applications.

2. mRNA Vaccine Manufacturing

MC3‑based LNPs have been employed in preclinical and clinical studies for mRNA vaccine delivery, including COVID‑19, influenza, and personalized cancer vaccines.

3. CRISPR‑Cas9 Gene Editing Delivery

DLin-M-C3-DMA is used in LNPs for the delivery of CRISPR‑Cas9 mRNA and guide RNA for therapeutic gene editing in preclinical models of genetic disorders.

4. LNP Formulation Optimization

Pharmaceutical scientists use MC3 as a benchmark ionizable lipid to optimize LNP manufacturing parameters, compare novel lipid candidates, and develop high‑potency nucleic acid delivery systems.

5. Analytical Method Development for LNPs

Reference grade DLin-M-C3-DMA serves as a standard for developing and validating HPLC, LC‑MS, and other analytical methods for quantifying ionizable lipid content in LNP drug products.

6. Quality Control Release Testing

Essential reference standard for QC release testing of MC3‑based LNP drug products, including identity, purity, and content uniformity assays.

7. In Vitro and In Vivo Gene Silencing Studies

Used in cell culture and animal model studies to evaluate siRNA‑mediated gene silencing potency, with established ED₅₀ values (0.005 mg/kg in murine FVII model) serving as benchmarks for novel LNP formulations.

Contact Us

Looking for the gold standard ionizable lipid for your siRNA or mRNA delivery program? Cosperpharm supplies high‑purity DLin-M-C3-DMA with comprehensive documentation to support your research and regulatory submissions. Contact our team to request a quote, discuss custom packaging, or arrange a technical consultation.